Cited by 252BRCA gene mutations in cancerPancreatic and Hepatic Oncology ResearchGenetic factors in colorectal cancer

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

Open access

, the Hereditary Breast Cancer Study Group, Iqbal, J, Ragone, A, Lubinski, J, Lynch, H T, Moller, P, Ghadirian, P, Foulkes, W D, Armel, S, Eisen, A, Neuhausen, S L, Senter, L, Singer, C F, Ainsworth, P, Kim-Sing, C, Tung, N, Friedman, E, Llacuachaqui, M, Ping, S, Narod, S A·2012·British Journal of Cancer

DOI 10.1038/bjc.2012.483PMC PMC3516682

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Germline mutations in BRCA1 and BRCA2 predispose to pancreatic cancer. We estimated the incidence of pancreatic cancer in a cohort of female carriers of BRCA1 and BRCA2 mutation. We also estimated survival rates in pancreatic cancer cases from families with a BRCA mutation. METHODS: We followed 5149 women with a mutation for new cases of pancreatic cancer. The standardised incidence ratios (SIR) for pancreatic cancer were calculated based on age group and country of residence. We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer. We recorded the year of diagnosis and the year of death for 351 identified cases. RESULTS: Eight incident pancreatic cancer cases were identified among all mutation carriers. The SIR for BRCA1 carriers was 2.55 (95% CI=1.03-5.31, P=0.04) and for BRCA2 carriers was 2.13 (95% CI=0.36-7.03, P=0.3). The 5-year survival rate was 5% for cases from a BRCA1 family and 4% for cases from a BRCA2 family. CONCLUSION: The risk of pancreatic cancer is approximately doubled in female BRCA carriers. The poor survival in familial pancreatic cancer underscores the need for novel anti-tumoural strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/bjc.2012.483

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Cancer risks in BRCA2 mutation carriers.
Olsson, H. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,404
Cancer Incidence in BRCA1 mutation carriers.
Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M. E. M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,132
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826 · cited 2×
“These include BRCA1 and BRCA2 (Lal et al, 2000), TP53 (Caldas et al, 1994), PALB2 (Jones et al, 2009), p16/CDKN2A (Redston et al, 1994; Ghiorzo et al, 2012), SMAD4 (Hahn et al, 1996), STK 11 (Sato et al, 2001), ataxia-telangiectasia-mutated (ATM) gene (Roberts et al, 2011) and the mismatch repair genes (MMR) (Win et a…”
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Self-citation
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491 · cited 1×
“…(Lal et al, 2000), TP53 (Caldas et al, 1994), PALB2 (Jones et al, 2009), p16/CDKN2A (Redston et al, 1994; Ghiorzo et al, 2012), SMAD4 (Hahn et al, 1996), STK 11 (Sato et al, 2001), ataxia-telangiectasia-mutated (ATM) gene (Roberts et al, 2011) and the mismatch repair genes (MMR) (Win et al, 2012).”
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.
Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., & Kern, S. E. (1994) · PubMed · Cited by 451
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.
Win, A. K., Young, J., Lindor, N., Tucker, K., Ahnen, D., Young, G., Buchanan, D., Clendenning, M., Giles, G., Winship, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5590 · Cited by 324
STK11/LKB1 Peutz-Jeghers Gene Inactivation in Intraductal Papillary-Mucinous Neoplasms of the Pancreas
Sato, N., Rosty, C., Jansen, M., Fukushima, N., Ueki, T., Yeo, C. J., Cameron, J. L., Iacobuzio–Donahue, C. A., Hruban, R. H., & Goggins, M. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63053-2 · Cited by 268

Flagged first, then by citations

Show all 19 references

1 of the 19 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 252

NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer
SAU, A. C., Cabrita, M. A., & Pratt, M. A. C. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0225 · Cited by 18
BRCA1 and BRCA2 – update and implications on the genetics of breast cancer: a clinical perspective
Foulkes, W. D. (2013) · Clinical Genetics · doi:10.1111/cge.12291 · Cited by 19
Self-citation
Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population
Darooei, M., Poornima, S., Salma, B. U., Iyer, G. R., Pujar, A., Srirambhatla, A., Shah, A., Maddali, S., & Hasan, Q. A. (2017) · Tumor Biology · doi:10.1177/1010428317694303 · Cited by 19
Pancreatic Cancer Screening
Das, K. K., & Early, D. S. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0149-8 · Cited by 19
AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 carriers: Commentary
Kupfer, S., Gupta, S., Weitzel, J., & Samadder, J. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.086 · Cited by 18
Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients
Tedaldi, G., Tebaldi, M., Zampiga, V., Cangini, I., Pirini, F., Ferracci, E., Danesi, R., Arcangeli, V., Ravegnani, M., Martinelli, G., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10050269 · Cited by 21
Identification of high-risk germline variants for the development of pancreatic cancer: Common characteristics and potential guidance to screening guidelines
Bennett, C. F., Suguitan, M. D., Abad, J., & Chawla, A. (2022) · Pancreatology · doi:10.1016/j.pan.2022.05.005 · Cited by 18
Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer
Liu, J., Mroczek, M., Mach, A., Stępień, M., Aplas, A., Pronobis‐Szczylik, B., Bukowski, S., Mielczarek, M., Gajewska, E., Topolski, P., et al. (2023) · Cancers · doi:10.3390/cancers15030779 · Cited by 18
BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping
Sharma, M. B., Carus, A., Sunde, L., Hamilton-Dutoit, S. J., & Ladekarl, M. B. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1044023 · Cited by 18
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
Karakasis, K., Burnier, J. V., Bowering, V. L., Oza, A. M., & Lheureux, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00119 · Cited by 18
Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report
Shimmura, H., Kuramochi, H., Jibiki, N., Katagiri, S., Nishino, T., & Araida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz141 · Cited by 17
Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma
Fountzilas, E., Eliades, A., Koliou, G.-A., Achilleos, A., Loizides, C., Tsangaras, K., Pectasides, D. G., Sgouros, J., Papakostas, P., Rallis, G., et al. (2021) · Cancers · doi:10.3390/cancers13020198 · Cited by 17
Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)
Barros, A., Pulido, C., Machado, M., Brito, M. J., Couto, N., Sousa, O., Melo, S. A., & Mansinho, H. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5290 · Cited by 20
The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation
Katona, B. W., Lubiński, J., Pal, T., Huzarski, T., Foulkes, W. D., Møller, P., Eisen, A. F., Armel, S. R., Neuhausen, S. L., Raj, R., et al. (2024) · Cancer · doi:10.1002/cncr.35666 · Cited by 16
Self-citation
Novel Therapeutics for Pancreatic Adenocarcinoma
Lowery, M. A., & O'Reilly, E. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.006 · Cited by 16
BRM polymorphisms, pancreatic cancer risk and survival
Segedi, M., Anderson, L. N., Espin‐Garcia, O., Borgida, A., Bianco, T., Cheng, D., Chen, Z., Patel, D., Brown, M. C., Xu, W., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30369 · Cited by 16
Genetic testing in women with breast cancer: implications for treatment
Paterson, R. J., & Phillips, K. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1374175 · Cited by 16
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
Molinaro, E., Andrikou, K., Gardini, A. C., & Rovesti, G. (2020) · Cancers · doi:10.3390/cancers12113346 · Cited by 15
Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes
Alzhrani, R. M., Alsaab, H. O., Vanamala, K., Bhise, K., Tatiparti, K., Barari, A., Sau, S., & Iyer, A. K. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000262 · Cited by 16
DNA glycosylase activity and cell proliferation are key factors in modulating homologous recombination in vivo
Kiraly, O., Gong, G., Roytman, M., Yamada, Y., Samson, L. D., & Engelward, B. P. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu177 · Cited by 15
Geographical, ethnic, and genetic differences in pancreatic cancer predisposition
Liew, S. Z. H., Ng, K. W., Ishak, N. D. B., Lee, S. Y., Zhang, Z., Chiang, J., & Ngeow, J. Y. Y. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-8 · Cited by 14
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
Teo, M. Y., & O'Reilly, E. M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.05.04 · Cited by 14
BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
Park, J. H., Jo, J. H., Jang, S. I., Chung, M. J., Park, J. Y., Bang, S., Park, S. W., Song, S. Y., Lee, H. S., & Cho, J. H. (2022) · Cancers · doi:10.3390/cancers14010236 · Cited by 14
Current status of inherited pancreatic cancer
Olakowski, M., & Bułdak, Ł. (2022) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-022-00224-2 · Cited by 16
Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance
Surowy, H., Sutter, C., Mittnacht, M., Klaes, R., Schaefer, D., Evers, C., Burgemeister, A. L., Goehringer, C., Dikow, N., Heil, J., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2943-5 · Cited by 14
Screening to Detect Precursor Lesions of Pancreatic Adenocarcinoma in High-risk Individuals: A Single-center Experience
Lachter, J., Rosenberg, C., Hananya, T., Khamaysi, I. N., Klein, A., Yassin, K., & Half, E. (2018) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10353 · Cited by 14
BRCAness and prostate cancer: diagnostic and therapeutic considerations
Dhawan, M., & Ryan, C. J. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0069-2 · Cited by 14
Biomarkers for personalized medicine in GI cancers
Zhang, S. Y., Zhang, S. Q., Nagaraju, G. P., & El‐Rayes, B. F. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.002 · Cited by 13
Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer
Maginn, E. N., de Sousa, C. H., Wasan, H. S., & Stronach, E. A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.002 · Cited by 14
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses
Shevach, J. W., Xu, J., Snyder, N. A., Wei, J., Shi, Z., Tran, H., Zheng, S. L., Beebe‐Dimmer, J., & Cooney, K. A. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2879 · Cited by 15
Prevalence of Variants of Uncertain Significance in Patients Undergoing Genetic Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome
Chrysafi, P., Jani, C., Lotz, M. M., Omari, O. A., Singh, H., Stafford, K., Agarwal, L., Rupal, A., Dar, A. Q., Dangelo, A., et al. (2023) · Cancers · doi:10.3390/cancers15245762 · Cited by 12
Pancreatic cancer in Saudi Arabia (2005–2020): increasing trend
Elwali, N. E., AlShareef, S. M., Khamis, A. H., & Elhassan, M. M. A. (2024) · BMC Cancer · doi:10.1186/s12885-024-12401-8 · Cited by 12
Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins
Jaballah-Gabteni, A., Tounsi, H., Kabbage, M., Hamdi, Y., Elouej, S., Ayed, I. B., Medhioub, M., Mahmoudi, M., Dallali, H., Yaïche, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1961-9 · Cited by 12
The impact of a cascade testing video on recipients’ knowledge, cognitive message processing, and affective reactions: A formative evaluation
Aeilts, A. M., Carpenter, K. M., Hovick, S. R. A., Byrne, L., Shoben, A. B., & Senter, L. A. (2020) · Journal of Genetic Counseling · doi:10.1002/jgc4.1345 · Cited by 12
Self-citation
The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants
Laish, I., Schechter, M., Dancour, A., Lieberman, S., Levi, Z., Goldberg, Y., Kedar, I., Hasnis, E., Half, E., Levi, G. R., et al. (2023) · Cancer · doi:10.1002/cncr.35052 · Cited by 12
Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions
Lheureux, S., Karakasis, K., Harter, P., Scott, C. L., Bacon, M. A., Bryce, J., Fur, N. L., Pujade-Lauraine, É., & Oza, A. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.10.010 · Cited by 11
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient
Kwong, A., Ho, C. Y. S., Shin, V. Y., Au, C. H., Chan, T. L., & Ma, E. S. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020889 · Cited by 11
Identification of Germline Mutations in Upper Tract Urothelial Carcinoma With Suspected Lynch Syndrome
Guan, B., Wang, J., Li, X., Lin, L., Fang, D., Kong, W., Tian, C., Li, J., Yang, K., Han, G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.774202 · Cited by 11
BRCA and Pancreatic Cancer
Brennan, G. T., Relias, V., & Saif, M. W. (2013) · PubMed · doi:10.6092/1590-8577/1652 · Cited by 11
The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer
Weng, C., Lin, Y., & Cheng, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091369 · Cited by 12
Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C
Chen, X., Peng, F., Ji, Y., Xiang, H., Wang, X., Liu, T., Wang, H., Han, Y., Wang, C., Zhang, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03013-8 · Cited by 13
Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis
Barzola, E., López, E. V., Quijano, Y., Caruso, R. R. C., Ferri, V., Durand, H., Fabra, I., Eduardo, D., Ielpo, B., Glagolieva, A., et al. (2019) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2019.23.2.200 · Cited by 10
EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer
Katona, B. W., Long, J. M., Ahmad, N. A., Attalla, S., Bradbury, A. R., Carpenter, E. L., Clark, D. F., Constantino, G., Das, K. K., Domchek, S. M., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0161 · Cited by 10
Stratifying Risk for Pancreatic Cancer by Multiplexed Blood Test
Digiacomo, L., Quagliarini, E., Pozzi, D., Coppola, R., Caracciolo, G., & Caputo, D. D. (2023) · Cancers · doi:10.3390/cancers15112983 · Cited by 10
Squamous Cell Carcinoma of the Pancreas in a Patient with GermlineBRCA2Mutation-Response to Neoadjuvant Radiochemotherapy
Schultheis, A. M., Nguyen, G. P., Ortmann, M., Kruis, W., Büttner, R., Schildhaus, H., & Markiefka, B. (2014) · Case Reports in Oncological Medicine · doi:10.1155/2014/860532 · Cited by 10
Mechanisms of Gastrointestinal Malignancies
Katona, B. W., & Lynch, J. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00066-9 · Cited by 11
Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency
Guantay, L., Garro, C., Siri, S. O., Pansa, M. F., Ghidelli, S., Paviolo, N. S., Racca, A. C., Nicotra, V. E., Radu, C. G., Bocco, J. L., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100932 · Cited by 10
BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association
Waisbren, J., Uthe, R., Siziopikou, K. P., & Kaklamani, V. (2015) · BMJ Case Reports · doi:10.1136/bcr-2014-208830 · Cited by 10
Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
Nizi, M. G., Sarnari, C., & Tabarrini, O. (2023) · Molecules · doi:10.3390/molecules28155849 · Cited by 10
Identification of genes and candidate agents associated with pancreatic cancer
Wang, B., Liu, Z., Sun, S., & Zhao, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1009-3 · Cited by 9
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?
Fanale, D., Corsini, L. R., Pedone, E., Randazzo, U., Fiorino, A., Piazza, M. D., Brando, C., Magrin, L., Contino, S., Piraino, P., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104086 · Cited by 11
Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer
Zhou, B., Zhang, S., Chen, G., & Chen, P. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i35.5094 · Cited by 8
Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan
Kitamura, H., Morizane, C., Tanabe, N., Ikeda, G., Maruki, Y., Ohba, A., Nagashio, Y., Kondo, S., Hijioka, S., Ueno, H., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.10.017 · Cited by 8
Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study
Cao, C., Sharib, J. M., Blanco, A. M., Goldberg, D., Bracci, P. M., Mukhtar, R. A., Esserman, L. J., & Kirkwood, K. S. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.09.019 · Cited by 8
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB)
Pijnappel, E. N., Suurmeijer, J. A., Koerkamp, B. G., Kos, M., Siveke, J. T., Salvia, R., Ghaneh, P., van Eijck, C. H. J., van Etten‐Jamaludin, F. S., Abrams, R. A., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0168 · Cited by 8
Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta‐analysis
McGarry, J., Creavin, B., Kelly, M. E., & Gallagher, T. K. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26994 · Cited by 8
Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series
McVeigh, T. P., Cody, N., Carroll, C., Duff, M., Farrell, M., Bradley, L., Gallagher, D. J., McDevitt, T., & Green, A. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.02.001 · Cited by 8
New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer
Verdaguer, H., Arroyo, A., & Macarulla, T. M. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0609-7 · Cited by 8
Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program
Dwarte, T. M., McKay, S., Johns, A. L., Tucker, K., Spigelman, A. D., Williams, D. B., & Stoita, A. (2019) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-019-0129-1 · Cited by 8
Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants
Shah, I., Silva-Santisteban, A., Germansky, K. A., Kandasamy, C., Mlabasati, J., Huang, D. C., Wadhwa, V., Bilal, M., & Sawhney, M. (2022) · Pancreas · doi:10.1097/mpa.0000000000002104 · Cited by 7
Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples
Árvai, K., Horváth, P., Balla, B., Tõkés, A., Tóbiás, B., Takács, I., Nagy, Z., Lakatos, P. L., & Kosa, J. P. (2014) · Familial Cancer · doi:10.1007/s10689-014-9730-7 · Cited by 7
Analysis of multiple primary cancer autopsy cases associated with breast cancer: 2002–2010
Shibahara, Y., Sugawara, Y., Miki, Y., Hata, S., Takahashi, H., Nakamura, Y., Suzuki, T., Ohuchi, N., Tsuji, I., & Sasano, H. (2016) · Pathology International · doi:10.1111/pin.12484 · Cited by 7
Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines
Thongchot, S., Jamjuntra, P., Prasopsiri, J., Thuwajit, P., Sawasdee, N., Poungvarin, N., Warnnissorn, M., Sa-nguanraksa, D., O‐charoenrat, P., Yenchitsomanus, P., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8205 · Cited by 7
Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2
Saldia, A., Olson, S. H., Nunes, P., Liang, X., Samson, M. L., Salo‐Mullen, E. E., Marcell, V. J., Stadler, Z. K., Allen, P. J., Offit, K., et al. (2019) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-18-0272 · Cited by 7
Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects
Boubaddi, M., Rossi, J., Marichez, A., Marty, M., Amintas, S., Laurent, C., & Dabernat, S. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17062-w · Cited by 6
Concurrent GermlineBRCA1/2and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options
Özer, M., Ranganathan, M., Lecomte, N., Schvartzman, J. M., Walch, H. S., Chatila, W. K., Hong, J., Carlo, M. I., Walsh, M. F., Sheehan, M. R., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00560 · Cited by 7
Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations
Salyer, C., Kobelka, C., Barrie, A. M., Weintraub, M. R., & Powell, C. B. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.017 · Cited by 6
Malignant Transformation of Heterotopic Pancreatic Tissue in a Patient with BRCA2 Mutation
Yeo, D. X. W., Goh, N., Chuah, K. L., Amitbhai, S. K., Oo, A. M., Ahmed, A. K. S., & Nath, K. A. (2021) · Gastroenterology Insights · doi:10.3390/gastroent12010002 · Cited by 6
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer
Mavromatis, L. A., Zlatanic, V., Agarunov, E., Sanoba, S. A., Kluger, M. D., Horwitz, L. I., Razavian, N., Maitra, A., Gonda, T. A., & Grams, M. E. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.0372 · Cited by 5
Association between fumarate hydratase variant subtypes and the risk of HLRCC-associated renal cell carcinoma: systematic review and meta-analysis
Wang, H., Rehim, S., & Wang, H. (2025) · Human Genomics · doi:10.1186/s40246-025-00797-8 · Cited by 5
CTRC gene polymorphism may increase pancreatic cancer risk – preliminary study
Głuszek, S., Kowalik, A., Kozieł, D., Wawrzycka, I., Głuszek–Osuch, M., & Matykiewicz, J. (2017) · Polish Journal of Surgery · doi:10.5604/01.3001.0010.5411 · Cited by 5
Screening patients at high risk for pancreatic cancer—Is it time for a paradigm shift?
Lo, W. M., Morris, M. C., Ahmad, S. A., & Patel, S. H. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25616 · Cited by 5
Risk of melanoma among people with BRCA1 and BRCA2 pathogenic variants: A systematic review and meta-analysis
Frontera, N., Ahsan, M. D., Chandler, I. R., Levi, S. R., Brewer, J., Weiss, J. M., Ma, X., Jewell, S., Sharaf, R., & Frey, M. K. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.08.030 · Cited by 4
BRCAShare —Assessment of an animated digital message for intrafamilial communication of pathogenic variant positive test results: A feasibility study
Aeilts, A. M., Carpenter, K. M., Hovick, S. R. A., Byrne, L., Shoben, A. B., & Senter, L. A. (2022) · Journal of Genetic Counseling · doi:10.1002/jgc4.1656 · Cited by 4
Self-citation
Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies
To, Y. H., Lee, B., Wong, H., Gibbs, P., & Tie, J. (2020) · Visceral Medicine · doi:10.1159/000509657 · Cited by 4
Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
Kwon, W. K., Jang, H.-J., Lee, J. E., Park, Y. H., Ryu, J. M., Yu, J., Jang, J., & Kim, J. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.05.042 · Cited by 4
RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma
Xie, F., Ding, D., Lin, C., Cunningham, D., Wright, M. J., Javed, A. A., Azad, N. A., Lee, V., Donehower, R. C., Jesus‐Acosta, A. D., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00404 · Cited by 4
Hepatic Lesions Detected after Mastectomy, in Breast Cancer Patients with Hepatitis Background May Need to Undergo Liver Biopsy to Rule Out Second Primary Hepatocellular Carcinoma
Chen, Q.-W., Li, H.-J., Chen, Y.-N., Ning, Z.-Y., Gao, S., Shen, Y., Meng, Z.-Q., Vargulick, S., Wang, B.-Y., & Chen, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0139782 · Cited by 4
Macrophages—Target and Tool in Tumor Treatment: Insights from Ovarian Cancer
Górczak, M., & Kiraga, Ł. (2025) · Cancers · doi:10.3390/cancers17193182 · Cited by 4
Revisiting the molecular landscape of Rosai-Dorfman disease: insights from whole exome sequencing of Saudi patients
Binhassan, S., Samman, M. M., Al‐Sheikh, Y. A., Alshakweer, W., Alhalouly, T., Alshamlan, N., & Abudawood, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1556830 · Cited by 3
The Early Detection of Pancreatic Cancer: Whom and How?
Ryu, J. K. (2015) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2015.20.4.198 · Cited by 3
Diagnosis and Management of Hereditary Pancreatic Cancer
Humphris, J. L., & Biankin, A. V. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-29998-3_5 · Cited by 3
The IGF-I/IGF-IR Signaling System and Pancreatic Cancer
Kopantzev, E. P., Гранкина, Е. В., Kopantseva, M. R., & Sverdlov, E. D. (2017) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416817030041 · Cited by 3
A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk
Yu, Y., Chang, K., Chen, J., Bohlender, R. J., Fowler, J., Zhang, D., Huang, M., Chang, P., Li, Y., Wong, J., et al. (2021) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100078 · Cited by 3
Neurologic Complications of Gastrointestinal Cancer
Magge, R., & Diamond, E. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-57901-6_24 · Cited by 3
Characteristics of Pure Familial Pancreatic Cancer Families and Those with Additional Breast Cancer
Bartsch, D. K. (2020) · Open Access Journal of Oncology and Medicine · doi:10.32474/oajom.2020.04.000178 · Cited by 3
Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer
Pijnappel, E. N., Suurmeijer, J. A., Koerkamp, B. G., Siveke, J. T., Salvia, R., Ghaneh, P., Besselink, M. G., Wilmink, J. W., & van Laarhoven, H. W. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_8 · Cited by 3
Association of BRCA Mutations and Pancreatic Cancer
Chandan, S., Deliwala, S. S., Facciorusso, A., Mohan, B. P., Ramai, D., & Kochhar, G. S. (2022) · Pancreas · doi:10.1097/mpa.0000000000001956 · Cited by 3
Optimization of Quality Assurance to Increase Clinical Utility and Cost Effectiveness of Hereditary Cancer Testing
Smith, S., Marino, I., Schaller, J., Arnell, C., Moyes, K., & Manley, S. (2017) · Personalized Medicine · doi:10.2217/pme-2016-0091 · Cited by 3
What is the role of PARP inhibitors in pancreatic cancer?
Halder, R., & Shroff, R. T. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1816174 · Cited by 3
Comprehensive analysis of BRCA1/2 mutations, “BRCAness” and PARP inhibitors in melanoma
Stylianakis, D., Stylianakis, I., Benjamin, H. A., Martella, S., Tziotis, A., Pellegrino, B., Silva, P. D., Giannakis, M., Perrone, F., Lambertini, M., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104962 · Cited by 2
A prospective observational study of pancreatic cancer risk in men and women with pathogenic variants in BRCA1 or BRCA2
Grindedal, E. M., Zucknick, M., Hovland, S. T., Grimsrud, T. K., & Mæhle, L. (2025) · BJC Reports · doi:10.1038/s44276-025-00199-2 · Cited by 3
Catching pancreatic cancer early: Are we there yet?
Rasheed, A. R. A., Koh, R. Y., Lim, W.-M., Mai, C., & Looi, C.-K. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.12.001 · Cited by 2
Pancreatic Cancer: What About Screening and Detection?
Konstantinou, F., Syrigos, K., & Saif, M. W. (2013) · PubMed · doi:10.6092/1590-8577/1645 · Cited by 2
Risk of Pancreatic Cancer in Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Germline Variants: A Retrospective Cohort Study
Patel, N. J., Chen, Q., Luong, T. Q., & Wu, B. U. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000857 · Cited by 2
Metastatic Lobular Carcinoma of the Male Breast Masquerading as a Pancreatic Head Mass, a Diagnostic Dilemma—Rare Case and Literature Review
Mor, A., Das, S., Joshi, S. P., Chaudhari, V. A., & Desai, S. B. (2022) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0042-1742639 · Cited by 2
A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?
Furuse, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.039 · Cited by 2
Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population
Złowocka-Perłowska, E., Dębniak, T., Słojewski, M., Lemiński, A., Soczawa, M., van de Wetering, T., Trubicka, J., Kluźniak, W., Wokołorczyk, D., Cybulski, C., et al. (2021) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-020-00161-y · Cited by 2
Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model
Peters, M. L. B., Eckel, A. L., Lietz, A., Seguin, C. L., Mueller, P. P., Hur, C., & Pandharipande, P. V. (2022) · Pancreatology · doi:10.1016/j.pan.2022.05.003 · Cited by 2
Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer
Singer, C. F., Rappaport, C., Sopik, V., & Narod, S. A. (2014) · Clinical Genetics · doi:10.1111/cge.12478 · Cited by 2
Self-citation

Authors: T. H. B. C. S. G., Iqbal, J., Ragone, A., Lubinski, J., Lynch, H. T., Moller, P., Ghadirian, P., Foulkes, W. D., Armel, S., Eisen, A., Neuhausen, S. L., Senter, L., Singer, C. F., Ainsworth, P., Kim-Sing, C., Tung, N., Friedman, E., Llacuachaqui, M., Ping, S., & Narod, S. A.
Affiliations: Women’s College Hospital Research and Innovation Institute (CA)
International Hereditary Cancer Center (PL)
Creighton University (US)
McGill University (CA)
University of Toronto (CA)
Sunnybrook Health Science Centre (CA)
City Of Hope National Medical Center (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Comprehensive Cancer Center Vienna (AT)
BC Cancer Agency (CA)
Beth Israel Deaconess Medical Center (US)
Tel Aviv University (IL)
Corresponding author: Narod, S A
ORCID: Iqbal, J
Foulkes, W D
Armel, S
Eisen, A
Neuhausen, S L
Senter, L
Singer, C F
Ainsworth, P
Tung, N
Friedman, E
Narod, S A
Venue: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Published: 2012-10-25
Volume: 107
Issue: 12
Pages: 2005-2009
ISSN: 0007-0920 (ISSN-L)
1532-1827
DOI: 10.1038/bjc.2012.483
PMC: PMC3516682
OpenAlex: W2035801850
Cited by: 252
References: 19
Citations by year: 2026: 6 · 2025: 14 · 2024: 6 · 2023: 17 · 2022: 23 · 2021: 20 · 2020: 26 · 2019: 18 · 2018: 19 · 2017: 28 · 2016: 24 · 2015: 20 · 2014: 22 · 2013: 9
FWCI: 9.80
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
www.springer.com/tdm (unspecified)
Locations: British Journal of Cancer (publishedVersion, cc-by-nc-sa)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Funders: Canadian Cancer Society Research Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: pancreatic cancer, BRCA1 mutation carriers, BRCA2 mutation carriers, hereditary cancer predisposition, cancer incidence, standardized incidence ratio, survival rate, familial pancreatic cancer
MeSH terms: Adult, Aged, Female, Heterozygote, Humans, Middle Aged, Pancreatic Neoplasms, Cohort Studies, Incidence, Germ-Line Mutation, BRCA1 Protein, Genes, BRCA1, Genes, BRCA2, BRCA2 Protein, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks